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One of the most controversial issues in interventional
cardiology concerns the meaningfulness of elevated cardiac
enzymes after percutaneous coronary interventions. Both
single-center observational studies (1–3) and subset analyses
from multicenter clinical trials (4,5) have reported an
association between postprocedure creatine kinase-
myocardial band (CK-MB) elevations and adverse short-
and long-term clinical outcomes, including mortality. Other
investigators have failed to demonstrate this relationship,
maintaining that while cardiac enzymes are frequently
elevated after percutaneous coronary procedures, the prog-
nostic implications of this finding are unclear (6).
See page 1134
The controversy has generated a good deal of healthy
disagreement leading to debates at national meetings as well
as intensive efforts to further study the issue and address
some fundamentally important questions in clinical cardi-
ology. Among these questions are: What exactly defines a
myocardial infarction (MI) (7)?, and, What are the role and
importance of the coronary microcirculation during coro-
nary intervention (8)?
Apart from these useful intellectual exchanges, the con-
troversy has produced emotional responses that have served
to trivialize the issue, ignoring its potential impact on
patients’ outcomes. This is reflected in the phrases used by
cardiologists to explain the elevation of CK-MB isoenzymes
after coronary intervention (Table 1). The choice of words
is meant to suggest a benign laboratory finding that could
not possibly represent a meaningful clinical event such as an
MI. In fact, some clinicians go to great lengths to avoid
calling these events infarctions, instead employing these
other terms.
Why do many of us do this? The Hippocratic oath
instructs us to “first, do no harm.” When performing
interventional procedures, the goal is certainly to alleviate
the coronary obstruction without causing or inducing a
complication. It is difficult to accept that a procedure that is
performed with noble intentions can have adverse clinical
consequences, especially when these events are frequently
asymptomatic. In addition, coronary intervention is a
visually-driven procedure. Decisions regarding revascular-
ization are based upon a subjective visual interpretation of
the coronary angiogram, and a procedure is deemed suc-
cessful when there is a widely patent lumen without angio-
graphic evidence of complications such as abrupt closure,
dissection or side branch occlusions. Many, if not most,
postprocedure MIs are not visually apparent at the time of
the procedure and are, therefore, met with skepticism from
the visually oriented interventional cardiologist when the
laboratory data the next morning document an infarction.
The article by Saucedo et al. (9) in this issue of the Journal
is the latest attempt to examine the long-term implications
of CK-MB elevation after percutaneous coronary interven-
tion. This report is especially timely because it focuses on
patients receiving a coronary stent, the intervention most
commonly performed today (10). This single-center obser-
vational study reports on 900 consecutive patients who
underwent successful native-vessel stenting. Patients were
classified into three groups based on the maximum CK-MB
observed after the procedure: normal, elevation of one to
five times the local upper limit of normal and elevation of
greater than five times the upper limit of normal. The
patients were followed for a mean of 14 months for the
occurrence of death and other cardiac events. The authors
reported higher acute complications in both groups with
elevated cardiac enzymes compared with patients without
any enzyme elevation and a significantly increased risk of
late death for patients with a poststent peak CK-MB greater
than five times the upper limit of normal. Multivariate
analysis confirmed the significance of the mortality obser-
vation (odds ratio 3.25, 95% confidence interval [CI] 1.00 to
10.5, p 5 0.04).
The authors should be congratulated for collecting, ana-
lyzing and reporting these data, given that many interven-
tional cardiologists have chosen not to check routine cardiac
enzymes for patients having a successful procedure. Obser-
vational databases like this one provide insight into contem-
porary practices that complement the findings of random-
ized clinical trials, which, by their nature, enroll a more
selected group of patients. The authors carefully evaluated
the patients for a number of acute cardiac complications and
then followed them after discharge in a systematic fashion,
ascertaining follow-up data on 96% of them. Importantly,
the authors used multivariate analysis, which included
baseline clinical, as well as lesion and procedural variables, to
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test the added importance of the postprocedure CK-MB
values.
The authors chose to limit their report to patients having
successful stent procedures, defined as those having ,50%
residual stenosis and the absence of death, Q wave MI or
emergency or urgent coronary bypass surgery. As such, their
population differs from those described in the randomized
trials where patients are enrolled either just before or during
the procedure without regard to its ultimate success. The
authors also elected to exclude patients with baseline eleva-
tions in CK-MB in order, presumably, to simplify the
postprocedure CK-MB analysis. These two decisions, while
justifiable, undoubtedly produced a lower-risk population
than is typically seen with an “all-comers” analysis. Given
this fact, their findings are even more striking, consistent
with the notion that myocardial necrosis occurs commonly
after even uncomplicated coronary procedures and is asso-
ciated with significant late-term consequences (11).
More than 8% of patients with a successful stent proce-
dure had a postprocedure peak CK-MB of greater than five
times the upper limit of normal and a three-fold increased
risk of death compared with patients without any CK-MB
elevation. Given the relatively small number of patients in
this category, the CIs surrounding the mortality estimate are
quite broad. If these findings are borne out, the potential
public health and economic implications are enormous
because more than 800,000 coronary stents were implanted
in the U.S. in 1998 (12).
The authors noted that their group 2 patients (those with
enzymes greater than one to five times the normal limit) did
not have an increased risk of late mortality, and they
seemingly concluded that this group of patients is not at
increased risk of major adverse clinical events. Understand-
ing the findings associated with this group is important
because most of the controversy involves patients with an
intermediate level of enzyme elevations. In the current
study, this level of enzyme elevation was very common,
being observed in 238 patients (26.4%) after a successful
procedure. But in looking at the mean CK-MB levels in the
groups, it becomes apparent that the mean CK-MB in
group 2 is only approximately two times the upper limit of
normal. There is insufficient information to draw adequate
conclusions from Group 2 regarding the really controversial
subgroup of patients, those with CK-MB elevations three to
five times the upper limit of normal. Additionally, despite
the low level of peak enzyme elevations in group 2, they had
significantly more acute complications than the group with-
out any enzyme elevation, including more recurrent isch-
emia, repeat cardiac catheterizations and pulmonary edema.
The data are, thus, not at all at odds with other reports as
concluded by the authors. It would be useful to reexamine
these data using CK-MB as a continuous variable because
other investigators have suggested that there is an increased
risk associated with levels of CK-MB just above the upper
limit of normal (4).
The introduction of coronary stenting has revolutionized
the practice of interventional cardiology; the predominant
effect has been on reducing restenosis and the need for
repeat procedures and not on reducing the postprocedure
risk of death or MI (13). In the current study, all patients
had successful procedures, presumably with wide-open lu-
mens and good coronary blood flow. Why then was there a
.30% incidence of elevations in cardiac enzymes? Emerg-
ing data suggest that there is distal embolization of athero-
thrombotic material accompanying the plaque disruption
that is essential to the success of the interventional proce-
dure. Data from Neumann et al. (8) support the notion that
it is a disorder of microcirculatory flow that leads to a
disorder in ventricular function that might be responsible
for the adverse clinical consequences. As we are learning in
the setting of acute MI and reperfusion therapy, it may well
be that flow in the microcirculation is as important as flow
in the epicardial vessels (14).
Is all this discussion on postprocedure enzyme elevation
an academic controversy, or is the issue of CK-MB eleva-
tion important for the clinical community at large? As
pointed out by Saucedo et al. (9), this is a common question
that is still enmeshed in controversy, has produced an
enormous amount of data and has generated many emo-
tional discussions. There are major issues at stake. New
devices are being developed that may increase the risk of
myonecrosis after interventional procedures. If there is a
greater risk of late death associated with these increases in
cardiac enzymes, how should the clinical and regulatory
communities interpret these data? The platelet glycoprotein
IIb/IIIa inhibitors are becoming an increasingly used ad-
junctive therapy during percutaneous coronary intervention
(15). Their predominant effect is to lower the risk of
periprocedural MI and not to reduce the risk of death (16).
Again, in order for the clinical and regulatory communities
to assess the benefit of these new therapies, there must be
some agreement as to the meaningfulness of the event.
Along the same line of reasoning, the impact of “score-
cards” on clinical practice depends, in part, on there being
some consensus that there is clinical benefit in reducing the
risk of periprocedural MI. The recently reported one-year
mortality data from the Evaluation of Platelet Inhibition in
STENTing (EPISTENT) trial (17) suggest that there is a
continued accrual of clinical benefit after acute treatment
with both abciximab and stenting compared with either
Table 1. Terms Describing Postprocedure CK-MB Elevations
Infarctlet
Minor enzyme elevations
Insignificant enzyme elevations
Enzyme leaks
Enzyme bumps
MB efflux
MPEI
CK-MB 5 creatine kinase-myocardial band; MPEI 5 minimal postprocedure
enzyme increase.
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therapy given alone. Wider use of these expensive therapies
at the time of coronary intervention requires broader agree-
ment about the meaningfulness of the events being pre-
vented by the therapies.
Data provided by the work of Saucedo et al. (9) add
coronary stenting to the list of interventional devices that
cause myonecrosis even after a successful procedure and are
associated with an increased risk of death in patients having
enzyme elevations greater than 5 times the upper limit of
normal. More work needs to be done to develop a consensus
about what exactly constitutes a postprocedure MI, what
should be done to manage patients so affected and what
therapies can be developed and used to attenuate that risk.
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